{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:28:12Z","timestamp":1792200492870,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":782,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jtct.2021.01.018","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T17:48:22Z","timestamp":1611510502000},"page":"331.e1-331.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience"],"prefix":"10.1016","volume":"27","author":[{"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.01.018_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106266","article-title":"Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia\u2014a meta analysis","volume":"88","author":"Geng","year":"2020","journal-title":"Leukemia Res"},{"key":"10.1016\/j.jtct.2021.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0004","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.01.018_bib0006","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bmt.1705299","article-title":"Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia","volume":"37","author":"Passweg","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0007","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","article-title":"Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation","volume":"10","author":"Chang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0008","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MOH.0b013e3283582322","article-title":"Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts","volume":"19","author":"Chang","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0010","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1158\/1078-0432.CCR-18-1637","article-title":"Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission","volume":"25","author":"Lv","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.01.018_bib0011","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0012","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.01.018_bib0013","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/leu.2016.110","article-title":"Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.01.018_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4049\/jimmunol.146.5.1402","article-title":"Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice","volume":"146","author":"Eto","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0016","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.4049\/jimmunol.157.12.5284","article-title":"Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo","volume":"157","author":"Kong","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0017","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0018","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0019","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.01.018_bib0020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","article-title":"Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party","volume":"55","author":"Prata","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V48.1.63.63","article-title":"Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0022","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.01.018_bib0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Ozdemir","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtct.2021.01.018_bib0024","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0026","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2010.213","article-title":"Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia","volume":"46","author":"Dezern","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0027","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0028","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0029","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41409-020-0897-2","volume":"55","author":"ElGohary","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.bbmt.2019.01.017","article-title":"Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor","volume":"25","author":"Yang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0031","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bmt.2017.237","article-title":"Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia","volume":"53","author":"Xu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0032","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.bbmt.2018.05.015","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia","volume":"24","author":"Lu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0033","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/bmt.2016.281","article-title":"Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia","volume":"52","author":"Xu","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0034","doi-asserted-by":"crossref","first-page":"e13810","DOI":"10.1111\/ctr.13810","article-title":"Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study","volume":"34","author":"Zhang","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0035","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","article-title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study","volume":"129","author":"Mehta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0036","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2018.05.017","article-title":"Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis","volume":"133","author":"Yu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0037","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.01.018_bib0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.01.018_bib0039","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.01.018_bib0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:16Z","timestamp":1763002756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721006254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2666636721006254"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.01.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}